What Works for Depression?
An Evidence-based Comparison of Treatment Options

April 29, 2013

Bruce Seeman, Agency for Healthcare Research and Quality

Gerald Gartlehner, MD, MPH, RTI-International

Effective Health Care Program
Agenda

- AHRQ and the Effective Health Care Program
- Second-Generation Antidepressants for Treating Adult Depression—An Update from Dr. Gartlehner
- Questions and Answers
Web Conference Logistics

- Audio lines have been muted to minimize background noise.
- To ask a question:
  - **Use the WebEx Q&A function:** You may ask a question for the presenter at any time. Questions will be answered midway through and at the very end of the presentation.

  - If you are experiencing technical issues, you may also use the WebEx Q&A function to request help.

- Let us know what you think! Complete the evaluation form at the conclusion of the presentation. Look for the “Evaluation” pop-up.
Agency for Healthcare Research and Quality (AHRQ)

- **Mission:** To improve the quality, safety, efficiency, and effectiveness of health care for all Americans

- **Research:** ~80 percent of AHRQ's budget is invested in grants and contracts focused on improving health care

- **The AHRQ Effective Health Care Program (EHC):**
  - Provides current, unbiased evidence on clinical effectiveness of health care interventions
  - Focuses on patient-centered outcomes
  - Helps consumers, providers, and policy-makers make informed choices
  - Does not make treatment recommendations
  - Long-term goal: Improve health care quality and patient health outcomes through informed decision making by patients, providers, and policymakers
What is Comparative Effectiveness Research (CER)?

- Comparative effectiveness research — a type of patient-centered outcomes research — compares drugs, medical devices, tests, surgeries, or ways to deliver health care, so that patients and their families can make more informed choices.

- Findings are descriptive, not prescriptive, and are intended as tools for informed decision making, not recommendations.

- Findings highlight current evidence about effectiveness, risks, and side effects.
Second-Generation Antidepressants for Treating Adult Depression—An Update
Funding Support and Disclaimer

- Funded by the Agency for Healthcare Research and Quality (AHRQ) through Contract No. 290-2007-10056-1 to RTI International

- This presentation is provided to assist in decisionmaking and should not be construed to represent clinical recommendations or guidelines.

  
  Available at: www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Outline of Presentation

- Background

- Questions addressed in the CER on second-generation antidepressants for adults with depressive disorders:
  - Overall comparative effectiveness of treatments
  - Treating patients with unresponsive or recurrent disease
  - Treating depression with accompanying symptoms
  - Comparative adverse effects
  - Effectiveness and adverse effects in different patient subpopulations

- Clinical Implications and Conclusions
Depressive disorders such as major depressive disorder (MDD), dysthymia, and subsyndromal depression are serious, disabling illnesses.

MDD affects more than 16 percent of adults at some point during their lifetimes.

In any given year, about 7% of the US population suffer from a depressive episode.

Women are about twice as likely as men to develop a depressive disorder.

In 2000, the economic burden of depressive disorders in the United States was estimated to be $83.1 billion.
## Antidepressants Sales in the United States

<table>
<thead>
<tr>
<th>DISPENSED PRESCRIPTIONS MN</th>
<th>2011</th>
<th>2010</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL US MARKET</td>
<td>4,024</td>
<td>3,993</td>
<td>3,949</td>
<td>3,866</td>
</tr>
<tr>
<td>1 Antidepressants</td>
<td>264</td>
<td>254</td>
<td>247</td>
<td>241</td>
</tr>
<tr>
<td>2 Lipid Regulators</td>
<td>260</td>
<td>260</td>
<td>254</td>
<td>242</td>
</tr>
<tr>
<td>3 Narcotic Analgesics</td>
<td>238</td>
<td>244</td>
<td>241</td>
<td>239</td>
</tr>
<tr>
<td>4 Antidiabetics</td>
<td>173</td>
<td>172</td>
<td>169</td>
<td>166</td>
</tr>
<tr>
<td>5 Ace Inhibitors (Plain &amp; Combo)</td>
<td>164</td>
<td>168</td>
<td>166</td>
<td>163</td>
</tr>
<tr>
<td>6 Beta Blockers (Plain &amp; Combo)</td>
<td>161</td>
<td>162</td>
<td>163</td>
<td>164</td>
</tr>
<tr>
<td>7 Respiratory Agents</td>
<td>153</td>
<td>153</td>
<td>152</td>
<td>147</td>
</tr>
<tr>
<td>8 Anti-Ulcerants</td>
<td>150</td>
<td>147</td>
<td>146</td>
<td>139</td>
</tr>
<tr>
<td>9 Diuretics</td>
<td>128</td>
<td>131</td>
<td>132</td>
<td>135</td>
</tr>
<tr>
<td>10 Anti-Epileptics</td>
<td>128</td>
<td>122</td>
<td>116</td>
<td>110</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SPENDING $ BN</th>
<th>2011</th>
<th>2010</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL US MARKET</td>
<td>319.9</td>
<td>308.6</td>
<td>300.7</td>
<td>285.7</td>
</tr>
<tr>
<td>1 Oncologics</td>
<td>23.2</td>
<td>22.3</td>
<td>21.5</td>
<td>19.7</td>
</tr>
<tr>
<td>2 Respiratory Agents</td>
<td>21.0</td>
<td>19.3</td>
<td>18.1</td>
<td>16.0</td>
</tr>
<tr>
<td>3 Lipid Regulators</td>
<td>20.1</td>
<td>18.8</td>
<td>18.6</td>
<td>18.1</td>
</tr>
<tr>
<td>4 Antidiabetes</td>
<td>19.6</td>
<td>17.7</td>
<td>15.8</td>
<td>13.6</td>
</tr>
<tr>
<td>5 Antipsychotics</td>
<td>18.2</td>
<td>16.2</td>
<td>14.7</td>
<td>14.3</td>
</tr>
<tr>
<td>6 Autoimmune Diseases</td>
<td>12.0</td>
<td>10.6</td>
<td>9.7</td>
<td>8.6</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td>11.0</td>
<td>11.6</td>
<td>11.5</td>
<td><strong>11.7</strong></td>
</tr>
<tr>
<td>8 HIV Antivirals</td>
<td>10.3</td>
<td>9.3</td>
<td>8.2</td>
<td>7.1</td>
</tr>
<tr>
<td>9 Anti-Ulcerants</td>
<td>10.1</td>
<td>11.9</td>
<td>14.1</td>
<td>14.2</td>
</tr>
<tr>
<td>10 Narcotic Analgesics</td>
<td>8.3</td>
<td>8.4</td>
<td>8.0</td>
<td>7.3</td>
</tr>
</tbody>
</table>

Source: IMS Health, National Sales Perspectives, Feb 2012
“Me-too” Drugs

Drugs that are structurally very similar to already known drugs, with only minor differences.
Second-generation Antidepressants

Fluoxetine

Sertraline

Fluvoxamine

Duloxetine

Desvenlafaxine

Citalopram

Nefazodone

Escitalopram

Trazodone

Bupropion

Placebo

Paroxetine

Venlafaxine

Mirtazapine

2 trials
1 trial
3 trials
6 trials
3 trials
7 trials
1 trial
8 trials
3 trials
1 trial
1 trial
1 trial
5 trials
1 trial
4 trials
1 trial
3 trials
8 trials
3 trials
1 trial
1 trial
1 trial
1 trial
1 trial
1 trial
Controversy about Comparative Effectiveness

Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians

Gerald Gartlehner, MD, MPH; Bradley N. Gaynes, MD, MPH; Richard A. Hansen, PhD, RPh; Patricia Thieda, MA; Angela DeVoe-Olcss, MS; Erin E. Krebs, MD, MPH; Charity C. Moore, PhD, MSPH; Laura Morgan, MA; and Kathleen A. Lohr, PhD

...no substantial differences in efficacy among second-generation antidepressants

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

Dr Andrea Cipriani PhD ①, Toshiaki A. Furukawa MD ②, Georgia Salanti PhD ①, John R. Geddes MD ①, Julian P. T. Higgins PhD ①, Rachel Churchill PhD ①, Norio Watanabe PhD ②, Atsuo Nakagawa MD ②, Ichiro M. Omori PhD ②, Hugh McGuire MA ①, Michele Tansella MD ①, Corrado Barbui MD ①

...escitalopram and sertraline have a more beneficial efficacy/harms profile than other antidepressants.
Effective Health Care Program
Comparative Effectiveness Review
Number 46

Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review

Medicines for Treating Depression
A Review of the Research for Adults
Population of interest

Adult outpatients with

- Major depressive disorder
- Dysthymia
- Subsyndromal depression
Phases of Treatment for Major Depression

<table>
<thead>
<tr>
<th>Treatment Phases</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute (6-12 weeks)</td>
<td></td>
</tr>
<tr>
<td>Continuation (4-9 months)</td>
<td></td>
</tr>
<tr>
<td>Maintenance (≥ 1 year)</td>
<td></td>
</tr>
</tbody>
</table>

Source: Recreated based on Kupfer, 1991
Second-Generation Antidepressants Included in the 2011 Updated Review

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>U.S. Trade Name*</th>
<th>Labeled Usesb</th>
<th>Therapeutic Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion†</td>
<td>Wellbutrin*; Wellbutrin SR*; Wellbutrin XL*</td>
<td>MDD; seasonal affective disorder</td>
<td>Other</td>
</tr>
<tr>
<td>Citalopram‡</td>
<td>Celexa*</td>
<td>MDD</td>
<td>SSRI</td>
</tr>
<tr>
<td>Desvenlafaxine†</td>
<td>Pristiq*</td>
<td>MDD</td>
<td>SNRI</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>Cymbalta*</td>
<td>MDD; GAD; neuropathic pain; fibromyalgia</td>
<td>SSNRI</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>Lexapro*</td>
<td>MDD; GAD</td>
<td>SSRI</td>
</tr>
<tr>
<td>Fluoxetine§</td>
<td>Prozac*; Prozac Weekly*</td>
<td>MDD; OCD; PMDD; panic disorder; bulimia nervosa</td>
<td>SSRI</td>
</tr>
<tr>
<td>Fluvoxamine§</td>
<td>Luvox*</td>
<td>OCD</td>
<td>SSRI</td>
</tr>
<tr>
<td>Mirtazapine§</td>
<td>Remeron*; Remeron SolTab*</td>
<td>MDD</td>
<td>Other</td>
</tr>
<tr>
<td>Nefazodone§</td>
<td>Serzone*</td>
<td>MDD</td>
<td>Other</td>
</tr>
<tr>
<td>Paroxetine§</td>
<td>Paxil*; Paxil CR*</td>
<td>MDD; OCD; panic disorder; social anxiety disorder; GAD; PTSD; PMDD§</td>
<td>SSRI</td>
</tr>
<tr>
<td>Sertraline§</td>
<td>Zoloft*</td>
<td>MDD; OCD; panic disorder; PTSD; PMDD; social anxiety disorder</td>
<td>SSRI</td>
</tr>
<tr>
<td>Trazodone§</td>
<td>Desyrel*</td>
<td>MDD</td>
<td>Other</td>
</tr>
<tr>
<td>Venlafaxine§</td>
<td>Effexor*; Effexor XR*</td>
<td>MDD; GAD§ panic disorder; social anxiety disorder§</td>
<td>SNRI</td>
</tr>
</tbody>
</table>

* CR = controlled release; SR = sustained release; XL or XR = extended release
b GAD = generalized anxiety disorder; MDD = major depressive disorder; OCD = obsessive-compulsive disorder; PMDD = premenstrual dysphoric disorder; PTSD = post-traumatic stress disorder; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; SSNRI = selective serotonin and norepinephrine reuptake inhibitor
† Desvenlafaxine was not included in the 2007 report but is included in the 2011 updated review.
‡ Only generic nefazodone is available in the United States.
§ Only Paxil CR (not Paxil) is approved for treating PMDD.
∥ Only Effexor XR (not Effexor) is approved for treating GAD and social anxiety disorder.
Methods

- Systematic literature search in multiple electronic databases (1980-2011)
- Extensive grey literature searches for unpublished studies
- Dual review of the literature
- Critical appraisal of the risk of bias of included studies.
- RCTs for efficacy and effectiveness, observational studies for harms
- Meta-analyses and network meta-analyses
- Grading of the strength of evidence with respect to important outcomes
The strength of evidence was classified into four broad categories:

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.</td>
</tr>
<tr>
<td>Low</td>
<td>Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.</td>
</tr>
<tr>
<td>Insufficient</td>
<td>Evidence either is unavailable or does not permit a conclusion.</td>
</tr>
</tbody>
</table>
# Outcomes of Interest

<table>
<thead>
<tr>
<th>Health Outcomes</th>
<th>Safety and Tolerability</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Response</td>
<td>• Overall adverse effects</td>
</tr>
<tr>
<td>• Remission</td>
<td>• Withdrawals</td>
</tr>
<tr>
<td>• Speed of response/remission</td>
<td>• Serious adverse events</td>
</tr>
<tr>
<td>• Relapse</td>
<td>• Specific adverse events including:</td>
</tr>
<tr>
<td>• Quality of life</td>
<td>• Hyponatremia</td>
</tr>
<tr>
<td>• Functional capacity</td>
<td>• Seizures</td>
</tr>
<tr>
<td>• Hospitalization</td>
<td>• Suicide</td>
</tr>
<tr>
<td></td>
<td>• Hepatotoxicity</td>
</tr>
<tr>
<td></td>
<td>• Weight gain</td>
</tr>
<tr>
<td></td>
<td>• Gastrointestinal symptoms</td>
</tr>
<tr>
<td></td>
<td>• Sexual side effects</td>
</tr>
<tr>
<td></td>
<td>• Others</td>
</tr>
</tbody>
</table>
Results

Identification
- 6,186 records identified through database searching
- 167 additional records identified through other sources

- 6,353 records identified (3,722 records after duplicates removed)

Screening
- 3,722 abstracts screened
- 2,265 citations excluded

Eligibility
- 1,457 full-text articles assessed for eligibility
- 228 studies (267 articles) included in qualitative synthesis

Included
- 92 studies included in quantitative synthesis (mixed treatment comparisons and meta-analyses)

1,190* full-text articles excluded:
- 7 Foreign languages
- 10 Too short of duration
- 84 Wrong population
- 142 Wrong drug
- 197 Wrong outcome
- 260 Wrong publication
- 279 Does not address outcomes of interest
- 464 Wrong design
- 79 Poor quality

*Multiple exclusion reasons are possible for each article
Results: Major Depressive Disorder

- 37% did not respond during 6 to 12 weeks of treatment; 53% did not achieve remission.

- The evidence is insufficient to determine factors that can reliably predict response or nonresponse in individual patients.
Results: Major Depressive Disorder

- Overall, similar efficacy, effectiveness, and effects on quality of life
  - Statistically significant differences are likely not clinically relevant
  - No differences between IR and XR formulations
    Strength of Evidence: Moderate

- Mirtazapine has a faster onset of action (1–2 weeks) than citalopram, fluoxetine, paroxetine, and sertraline;
  Response rates were similar after 4 weeks of treatment.
  Strength of Evidence: Moderate
Overall, similar efficacy between immediate (IR)- and extended- release (XR) formulations
- Fluoxetine daily vs. fluoxetine weekly
  Strength of Evidence: Moderate
- Paroxetine IR vs. paroxetine CR
  Strength of Evidence: Moderate
- Venlafaxine IR vs. venlafaxine XR
  Strength of Evidence: Low

Mixed evidence about better adherence and persistence with XR than IR medications
  Strength of Evidence: Moderate to Low
Results: Preventing Relapse and Maintaining Remission

- **Maintaining Remission**
  - Most second-generation antidepressants effectively maintain remission (prevent relapse and recurrence) with similar efficacy.
  
  **Strength of Evidence: Moderate**
Resistant or Refractory Depression

- Venlafaxine may be modestly superior to other selective serotonin reuptake inhibitors; however, results on comparative effectiveness are mixed.

Strength of Evidence: Low
QUESTIONS & ANSWERS
Treating Depression with Accompanying Symptoms

- Anxiety
- Insomnia
- Low Energy
- Melancholia
- Pain
- Psychomotor Change
- Somatization
Results: Treatment of Depression in Patients with Accompanying Symptom

- Similar efficacy for the treatment of depression in patients with accompanying symptoms

Strength of Evidence: Moderate (anxiety), low (insomnia), insufficient (low energy, melancholia, pain, psychomotor changes, somatization)
Similar efficacy for the treatment of anxiety, pain, insomnia in patients with depression

Strength of Evidence: Moderate (anxiety, pain), low (insomnia)

Insufficient evidence to determine the comparative efficacy of second-generation antidepressants in treating low energy, psychomotor changes, melancholia, or somatization.
Comparative Harms of Second-Generation Antidepressants

- Overall comparative risk of specific adverse events
- Discontinuation because of adverse events
- Risk of severe adverse events
Results: Risk of Harms

- Constipation, diarrhea, dizziness, headache, insomnia, nausea, sexual adverse events, and somnolence were commonly and consistently reported adverse events.

- 63 percent of patients in efficacy trials experienced at least one adverse event.

- Nausea and vomiting were the most common reasons for discontinuation in efficacy studies.
Overall rates of adverse events were similar among second-generation antidepressants, though incidence of specific adverse effects differed across antidepressants.

Strength of Evidence: High
### Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (1 of 3)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Outcome</th>
<th>Strength of Evidence</th>
</tr>
</thead>
</table>
| Nausea and Vomiting        | • Venlafaxine has a 52-percent higher incidence than selective serotonin reuptake inhibitors as a class.  
• When used to treat major depressive disorder, paroxetine IR may lead to higher rates of nausea than paroxetine CR. | High                 |
| Weight Gain                | Mirtazapine is associated with more weight gain than citalopram, fluoxetine, paroxetine, and sertraline (0.8–3.0 kg after 6–8 weeks). | High                 |
| Diarrhea                   | Sertraline was associated with an 8-percent higher incidence of diarrhea than bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, and venlafaxine. | Moderate            |
Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (2 of 3)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Outcome</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somnolence</td>
<td>Trazodone was associated with a 16-percent higher incidence of somnolence than bupropion, fluoxetine, mirtazapine, paroxetine, and venlafaxine.</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
| Sexual Dysfunction    | • Bupropion had fewer sexual side effects than escitalopram, fluoxetine, paroxetine, and sertraline.  
                           • Paroxetine had the highest rate of sexual side effects when compared with selective serotonin reuptake inhibitors as a class (16% vs. 6%).  
                           • Sexual side effects may occur at different rates between men and women. | High  
                           Moderate  
                           Low      |

MDD = major depressive disorder
Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (3 of 3)

<table>
<thead>
<tr>
<th>Adverse Effects</th>
<th>Outcomes</th>
<th>Strength of Evidence</th>
</tr>
</thead>
</table>
| Discontinuation Rates | • When compared with most SSRIs, higher discontinuation rates due to adverse effects were seen with duloxetine (67% higher risk) and venlafaxine (40% higher risk).  
  • Venlafaxine had lower discontinuation rates due to lack of efficacy (35% lower risk).                                                                                                      | High                 |
| Withdrawal Symptoms   | • The highest rates of withdrawal symptoms (headache, dizziness, light-headedness, nausea, and anxiety) were reported after discontinuation of paroxetine or venlafaxine.  
  • Fluoxetine had the lowest rate of withdrawal symptoms.                                                                                                                                       | Moderate             |

MDD = major depressive disorder; SSRI = selective serotonin reuptake inhibitor
The existing evidence on the comparative risk for rare but severe adverse events such as suicidality, seizures, cardiovascular events, hyponatremia, hepatotoxicity, and serotonin syndrome is insufficient to draw firm conclusions.
Results: Treating Depression in Subgroups

- Elderly patients (≥60 years) with MDD had similar efficacy with second-generation antidepressants. 
  **Strength of Evidence: Moderate**

- Elderly patients (≥60 years) with MDD may experience some differences in adverse events from these drugs. 
  **Strength of Evidence: Low**
Insufficient evidence about differences in efficacy, effectiveness, or risk of harms for subgroups with respect to sex, race or ethnicities, and co-morbidities.
Results: Dysthymia and Subsyndromal Depression

- No double-blinded head-to-head evidence is available

- Evidence is limited to fluoxetine, paroxetine, and sertraline

- Evidence about the general efficacy of antidepressants for the treatment of dysthymia and subsyndromal depression is mixed.

Strength of Evidence: Insufficient (dysthymia) and low (subsyndromal depression)
Clinical Implications and Conclusions

- Current evidence does not warrant the choice of one drug over another based on efficacy.

- Although second-generation antidepressants are similar in efficacy, they cannot be considered identical drugs.

- Evidence of high and moderate strength supports some differences among individual drugs with respect to onset of action, adverse events, and some measures of health-related quality of life.
Differences in adverse events or costs might influence the choice of a medication for an individual patient.

Given the fact that almost two in five patients do not respond to initial treatment, clinicians need to be familiar with different antidepressants.
Many thanks for your attention